Erectile Dysfunction Therapeutics - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the drug development landscape of the drug development for erectile dysfunction including molecules at pre-clinical, discovery, and other developmental stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapies employed, route of administration, therapeutic modality, targets for the drugs under development, and mechanism of action.

Overview of the drug development pipeline for erectile dysfunction

Erectile dysfunction (ED) is the type of sexual dysfunction when a man cannot maintain a firm erection of the penis or coitus. ED is also known as impotence and is more likely to happen in people with low blood pressure, blood clots, and heart problems. People suffering from this condition experience difficulty maintaining an erection during sexual activities and reduced sexual interests. Technavio’s market research analysts have predicted that with the introduction of urethral suppository medications, testosterone supplement therapy, penile pumps, and implants or surgery as some of the most promising approaches to treat erectile dysfunction, the global erectile dysfunction market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical and phase I developmental stages. For instance, sponsors such as BIOPHARM developed rhGDG-5 and Can-Fite BioPharm developed CF602, which are under pre-clinical development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under discovery, phase II, and phase I/II stages. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase III developmental stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of erectile dysfunction. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• BIOPHARM
• BIOZEUS
• Futura Medical

Therapeutic assessment of the drug development pipeline for erectile dysfunction by route of administration

• Topical
• Oral
• Intracavernous

The topical route of administration (ROA) involves the administration of drug substances directly to body surfaces such as the skin or mucous membranes. It has been observed that the majority of total therapeutics are being developed for topical administration.

Therapeutic assessment of the drug development pipeline for erectile dysfunction by therapeutic modality

• Small molecule
• Recombinant protein
• Stem cell

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for erectile dysfunction are being developed as small molecules. Small molecules bind with specific biological macromolecules and act as an effector and alter the activity or function of the target.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for erectile dysfunction?
• What are the companies that are currently involved in the development of drug molecules for erectile dysfunction?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.